This move is archived. Current quotes and coverage live on the stock page.
Get KNE alerts:
Kane Biotech Inc saw a significant drop in its stock price, raising concerns among investors.
Kane Biotech Inc (KNE.V) experienced a sharp decline in its stock price yesterday, closing down 16.67% at CA$0.03. This downturn has left many investors questioning the company's future prospects.
Advertisement
Kane Biotech Inc
KNE.V
KNE.V
Kane Biotech Inc
WealthAwesomeMarket cap
$6.15M
52W high
$0.05
52W low
$0.02
1W change
+0.00%
Beta
0.31
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on KNE's historical volatility
30-Day Vol
214.3%
Annualized
90-Day Vol
176.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.03
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.03 | C$0.01 – C$0.06 |
| 60 trading days | C$0.03 | C$0.01 – C$0.08 |
| 90 trading days | C$0.03 | C$0.01 – C$0.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: With a market cap of just CA$5.13 million and no recent positive news to boost investor sentiment, Kane Biotech's stock performance raises red flags for potential investors.
Stock Price Plummets by 16.67%
Kane Biotech's market cap now sits at just CA$5.13 million, highlighting the company's precarious financial position.
Bull case
If Kane Biotech can effectively leverage its recent commercial activities and successfully launch its revyve® Antimicrobial Wound Gel, there’s a chance that investor sentiment could improve.
Bear case
The absence of significant financial results and ongoing challenges in the shift to human wound care could keep the stock price down.
Advertisement
Market Reaction
Kane Biotech's stock performance reflects broader market concerns about its financial health. The company is transitioning from animal health to human wound care but hasn’t provided recent updates to reassure investors. The drop in stock price suggests that investors are cautious about the company's ability to manage this transition successfully.
Financial Overview
As of the last trading session, Kane Biotech's market cap stands at CA$5.13 million. With no dividend yield and a profit margin of 0%, the financial metrics indicate a company struggling to gain traction. Investors should carefully consider these factors when evaluating potential investments in Kane Biotech. For more details on the company's financial performance, you can check out their latest results.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
